Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 3/20 | 0.43 |
| ▸ | TYMS | P04818 | 4/20 | 0.42 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16487071 | 0.86 | HSP90AA1 (0.46) | LMNATSHRHSP90AA1ERBB2HSP90AB1 | |
| SCHEMBL3116678 | 0.84 | LMNA (0.68) | LMNATSHRHSP90AA1ERBB2HSP90AB1 | |
| SCHEMBL16486623 | 0.82 | HSP90AA1 (0.46) | LMNATSHRHSP90AA1ERBB2HSP90AB1 | |
| SCHEMBL1861838 | 0.82 | HSP90AA1 (0.69) | LMNATSHRHSP90AA1ERBB2HSP90AB1 | |
| SCHEMBL16486508 | 0.81 | LMNA (0.49) | LMNATSHRHSP90AA1ERBB2HSP90AB1 | |
| SCHEMBL16487138 | 0.81 | LMNA (0.46) | LMNATSHRHSP90AA1ERBB2HSP90AB1 | |
| SCHEMBL13845784 | 0.81 | PIK3CG (0.47) | LMNATSHRHSP90AA1ERBB2HSP90AB1 | |
| SCHEMBL15080556 | 0.79 | HSP90AA1 (0.49) | LMNATSHRHSP90AA1ERBB2HSP90AB1 | |
| SCHEMBL16486551 | 0.78 | HSP90AA1 (0.51) | LMNATSHRHSP90AA1ERBB2HSP90AB1 | |
| SCHEMBL5132695 | 0.78 | LMNA (0.48) | LMNATSHRDHFRTYMSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-04-14 | — | — | US | disclosed |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-04-20 | — | — | US | disclosed |
| US-11267816-B2 | Selective Grp94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-03-08 | — | — | US | disclosed |
| CN-105899503-B | Selective GRP94 inhibitors and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2020-08-18 | — | — | CN | disclosed |
| US-20200102312-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2020-04-02 | — | — | US | disclosed |
| US-10421758-B2 | Selective Grp94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-09-24 | — | — | US | disclosed |
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2016-07-07 | — | — | US | disclosed |
| EP-3033338-A2 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015023976-A2 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | LMNA 4391/4885TSHR 3467/4885HSP90AA1 9/4885 |
| US-10421758-B2 | Selective Grp94 inhibitors and uses thereof | HSP90B1, HSP90AB2P, HSPE1 | LMNA 4391/4885TSHR 3467/4885HSP90AA1 9/4885 |
| US-11267816-B2 | Selective Grp94 inhibitors and uses thereof | HSP90B1, HSP90AB2P, HSPE1 | LMNA 4391/4885TSHR 3467/4885HSP90AA1 9/4885 |
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | GRPR, HSPB1, HSP90AB2P | LMNA 3894/4885TSHR 454/4885HSP90AA1 14/4885 |
| US-20200102312-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | LMNA 4391/4885TSHR 3467/4885HSP90AA1 9/4885 |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | LMNA 4391/4885TSHR 3467/4885HSP90AA1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.